Acerus Pharmaceuticals (ASPCF) Posts Earnings Results, Misses Estimates By $0.01 EPS

Acerus Pharmaceuticals (OTCMKTS:ASPCF) released its quarterly earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01), reports. Acerus Pharmaceuticals had a negative net margin of 236.97% and a negative return on equity of 461.27%. The firm had revenue of $2.17 million for the quarter.

ASPCF opened at $0.12 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.35 and a quick ratio of 0.90. Acerus Pharmaceuticals has a fifty-two week low of $0.08 and a fifty-two week high of $0.34.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.

Featured Story: What is a Stop Order?

Earnings History for Acerus Pharmaceuticals (OTCMKTS:ASPCF)

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with's FREE daily email newsletter.